HeartFlow Inc. (HTFL) Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: Q2 revenue reached $64.1 million, up 48% year-over-year, with U.S. revenue increasing 51% to $59.6 million. This marks the fastest revenue growth in 8 quarters.

Plaque Revenue: Contributed $7.8 million, exceeding expectations.

Gross Margin: Non-GAAP gross margin improved to 83.3%, up from 75.6% in Q2 2025, driven by AI efficiencies and a higher mix of Plaque revenue.

Operating Loss: Non-GAAP operating loss narrowed to $7.9 million from $11.5 million a year ago, with a non-GAAP net loss of $5.8 million ($0.07 per share).

Cash Position: Ended the quarter with $246.8 million in cash and equivalents.

2Strategic Updates and Business Highlights

Commercial Momentum: Strong growth in new account additions, with 340 accounts from 2025 continuing to ramp. The installed base is projected to reach approximately 1,250 by year-end.

Product Innovations: Launched HeartFlow Plaque Staging, enhancing risk stratification for patients. PCI Navigator is gaining traction and is expected to strengthen market position.

Clinical Evidence: Continued to build a robust foundation with over 625 peer-reviewed publications and new data presented at SCCT, reinforcing the accuracy and utility of HeartFlow's products.

3Forward Guidance and Outlook

Revenue Guidance: Full-year revenue is now projected at $246 million to $250 million, reflecting 40% to 42% growth.

Plaque Revenue Outlook: Increased to $29 million to $31 million.

Gross Margin Guidance: Raised to approximately 82%, with a long-term target of 85% gross margin.

Profitability Timeline: On track to achieve cash flow profitability by mid-2028.

4Bad News, Challenges, or Points of Concern

Competition: While HeartFlow maintains a strong market position, competition is increasing as other vendors recognize the growth potential in the cardiovascular diagnostics space.

Regulatory Environment: The evolving landscape of reimbursement policies, particularly regarding AI-enabled software, may pose future challenges.

Market Dynamics: The company noted that Q2 performance was seasonally strong, and future quarters may not see the same level of growth, indicating potential volatility.

5Notable Q&A Insights

Plaque Adoption: The company is experiencing strong momentum in Plaque utilization, with physicians increasingly adopting the technology for a broader range of patients.

FFRCT Performance: There was significant growth in FFRCT utilization, attributed to improved performance in existing sites and new account ramp-up.

FDA and Regulatory Updates: HeartFlow is optimistic about the new CMS reimbursement framework for AI-enabled software, viewing it as a positive development for their business model.

Pricing Dynamics: The company expects pricing trends to stabilize, with no significant changes anticipated for the remainder of 2026, but a potential increase in early 2027. Overall, HeartFlow's Q2 2026 results reflect strong growth and strategic advancements, with a positive outlook tempered by competitive and regulatory challenges.